PROGEN was founded in 1983 by four scientists from Heidelberg, Germany, who joined forces to manufacture and supply high quality antibodies for biomedical research.

We help scientists worldwide drive biopharmaceutical and diagnostic progress to provide high-quality and reliable treatments for patients. Our mission is to make new therapies safe and affordable and to improve existing research processes. The PROGEN team consists of bioscientists and adeno-associated virus (AAV) experts who collaborate with specialists around the world. Our products are essentials for research in science and industry. We are more than just a manufacturer of antibodies, AAV gene therapy tools, density gradient media, and phage display technologies: We strive to understand the needs of scientists to develop solutions to jointly address challenges in academic research, biotechnology and pharma.

Since October 2012 Progen is a 100% subsidiary of the R-Biopharm AG. Together with the R-Biopharm Group Progen will further develop its product range in order to meet market needs and strengthen its core competence in the field of life science reagents.

Antibodies
Premium research antibodies - most published since 1983
AAV
Unique range of adeno-associated virus (AAV) antibodies and quantification ELISAs for gene therapy research
Antigens and Controls
Various purified and recombinant proteins to support your research
Density gradient media for the isolation of cells, subcellular membranes, viruses and macromolecules using centrifugation techniques
Diagnostic Assays
In vitro diagnostic (IVD) and research (RUO) tests based on ELISA technology and IFT/IFA
Phage Display
Antibody hyperphage display technology for the generation of recombinant antibodies, proteins or peptides - a leap forward in functional gene analysis
Staining Solutions for detection and visualization of specific primary antibody binding in tissue sections and cells.

1983